156 related articles for article (PubMed ID: 32710938)
1. Sumoylation in liver disease.
Zeng M; Liu W; Hu Y; Fu N
Clin Chim Acta; 2020 Nov; 510():347-353. PubMed ID: 32710938
[TBL] [Abstract][Full Text] [Related]
2. Small ubiquitin-related modifier 1 is involved in hepatocellular carcinoma progression via mediating p65 nuclear translocation.
Liu J; Tao X; Zhang J; Wang P; Sha M; Ma Y; Geng X; Feng L; Shen Y; Yu Y; Wang S; Fang S; Shen Y
Oncotarget; 2016 Apr; 7(16):22206-18. PubMed ID: 26993772
[TBL] [Abstract][Full Text] [Related]
3. Interplay between SUMO1-related SUMOylation and phosphorylation of p65 promotes hepatocellular carcinoma progression.
Jiang C; Zhang C; Dai M; Wang F; Xu S; Han D; Wang Y; Cao Y; Liang Y; Zhang Z; Yan L; Shen Y; He K; Shen Y; Liu J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119595. PubMed ID: 37730133
[TBL] [Abstract][Full Text] [Related]
4. SUMOylated CPAP is required for IKK-mediated NF-κB activation and enhances HBx-induced NF-κB signaling in HCC.
Yang ST; Yen CJ; Lai CH; Lin YJ; Chang KC; Lee JC; Liu YW; Chang-Liao PY; Hsu LS; Chang WC; Hung WC; Tang TK; Liu YW; Hung LY
J Hepatol; 2013 Jun; 58(6):1157-64. PubMed ID: 23369793
[TBL] [Abstract][Full Text] [Related]
5. The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development.
Yuan H; Lu Y; Chan YT; Zhang C; Wang N; Feng Y
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830854
[TBL] [Abstract][Full Text] [Related]
6. SUMO1 Modification Facilitates Avibirnavirus Replication by Stabilizing Polymerase VP1.
Wu H; Yang H; Ji G; Zheng T; Zhang Y; Deng T; Zheng X; Zhou J; Hu B
J Virol; 2019 May; 93(10):. PubMed ID: 30842328
[TBL] [Abstract][Full Text] [Related]
7. Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma.
Liu J; Sha M; Wang Q; Ma Y; Geng X; Gao Y; Feng L; Shen Y; Shen Y
BMC Cancer; 2015 Oct; 15():675. PubMed ID: 26458400
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis.
Yen CJ; Yang ST; Chen RY; Huang W; Chayama K; Lee MH; Yang SJ; Lai HS; Yen HY; Hsiao YW; Wang JM; Lin YJ; Hung LY
J Biomed Sci; 2019 Jun; 26(1):44. PubMed ID: 31170980
[TBL] [Abstract][Full Text] [Related]
9. IGF-II induced by hepatitis B virus X protein regulates EMT via SUMO mediated loss of E-cadherin in mice.
Ha HL; Kwon T; Bak IS; Erikson RL; Kim BY; Yu DY
Oncotarget; 2016 Aug; 7(35):56944-56957. PubMed ID: 27486970
[TBL] [Abstract][Full Text] [Related]
10. SUMOylation and phosphorylation cross-talk in hepatocellular carcinoma.
Tomasi ML; Ramani K
Transl Gastroenterol Hepatol; 2018; 3():20. PubMed ID: 29780898
[TBL] [Abstract][Full Text] [Related]
11. Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
Liu J; Wu Z; Han D; Wei C; Liang Y; Jiang T; Chen L; Sha M; Cao Y; Huang F; Geng X; Yu J; Shen Y; Wang H; Feng L; Wang D; Fang S; Wang S; Shen Y
Hepatology; 2020 Apr; 71(4):1262-1278. PubMed ID: 31469428
[TBL] [Abstract][Full Text] [Related]
12. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer.
Zubiete-Franco I; García-Rodríguez JL; Lopitz-Otsoa F; Serrano-Macia M; Simon J; Fernández-Tussy P; Barbier-Torres L; Fernández-Ramos D; Gutiérrez-de-Juan V; López de Davalillo S; Carlevaris O; Beguiristain Gómez A; Villa E; Calvisi D; Martín C; Berra E; Aspichueta P; Beraza N; Varela-Rey M; Ávila M; Rodríguez MS; Mato JM; Díaz-Moreno I; Díaz-Quintana A; Delgado TC; Martínez-Chantar ML
EBioMedicine; 2019 Feb; 40():406-421. PubMed ID: 30594553
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
Qin Y; Bao H; Pan Y; Yin M; Liu Y; Wu S; Li H
Mol Med Rep; 2014 Mar; 9(3):877-81. PubMed ID: 24399357
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation Landscape of Renal Cortical Collecting Duct Cells.
Wu Q; Aroankins TS; Cheng L; Fenton RA
J Proteome Res; 2019 Oct; 18(10):3640-3648. PubMed ID: 31502464
[TBL] [Abstract][Full Text] [Related]
15. The role and mechanism of SUMO modification in liver disease.
Li M; Zhang J; Li Z; Xu Z; Qian S; Tay LJ; Zhang Z; Yang F; Huang Y
Biomed Pharmacother; 2024 Jun; 177():116898. PubMed ID: 38878635
[TBL] [Abstract][Full Text] [Related]
16. The post-translational modification, SUMOylation, and cancer (Review).
Han ZJ; Feng YH; Gu BH; Li YM; Chen H
Int J Oncol; 2018 Apr; 52(4):1081-1094. PubMed ID: 29484374
[TBL] [Abstract][Full Text] [Related]
17. Abnormal protein SUMOylation in liver disease: novel target for therapy.
Yang Y; Yu F
J Mol Med (Berl); 2024 Jun; 102(6):719-731. PubMed ID: 38565749
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
19. Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.
Sengupta I; Das D; Singh SP; Chakravarty R; Das C
J Biol Chem; 2017 Dec; 292(50):20379-20393. PubMed ID: 29046350
[TBL] [Abstract][Full Text] [Related]
20. SUMOylation attenuates the transcriptional activity of the NF-κB subunit RelB.
Leidner J; Voogdt C; Niedenthal R; Möller P; Marienfeld U; Marienfeld RB
J Cell Biochem; 2014 Aug; 115(8):1430-40. PubMed ID: 24616021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
